A Covid-19 vaccine for kids being developed by Gujarat’s pharma player Zydus Cadila may not be available soon as India’s top drug regulator the Drugs Controller General of India (DCGI) may take additional time for granting it emergency approval, as per news reports.

Zydus Cadila on July 1 had applied for EUA or Emergency Use Approval for its DNA Covid-19 vaccine ZyCoV-D for children of 12 years and above, from DCGI. The company had handed over the interim results from the phase-III clinical trials conducted in more than 28,000 volunteers. The study was told to have shown

safety and efficacy in the interim data. It is planning to roll out 10 to 12 crore doses of the vaccine every year.

The company has reportedly said that the study was conducted during the peak of the Covid-19’s second wave in India. This reaffirms the efficacy of the vaccine against the new mutant strains, particularly the Delta variant.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.